Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

Slides:

Advertisements

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Advertisements

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

A girl with a solitary red bulla

Facial adenocarcinoma treated with intra-arterial chemotherapy

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, MD,

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort Shelley.

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Severe hypoglycemia after initiation of anti–tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2.

Alopecia areata Journal of the American Academy of Dermatology

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Treatment of psoriasis vulgaris using low-dose naltrexone

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Lip edema Journal of the American Academy of Dermatology

Mark D. Heibel, MD, Haley D. Heibel, MS JAAD Case Reports

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Leflunomide as adjuvant treatment of dermatomyositis

Seasonal patterns in alopecia areata, totalis, and universalis

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Adult-onset Still's disease revealed by facial edema

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials Kristian Reich, MD, Craig Leonardi, MD, PC, Richard G. Langley, MD, FRCPC, Richard B. Warren, MBChB (Hons), PhD, Hervé Bachelez, MD, PhD, Ricardo Romiti, MD, Mamitaro Ohtsuki, MD, PhD, Wen Xu, PhD, Nayan Acharya, MBBS, MRCP, MFPM, Kathleen Solotkin, MSN, Jean-Frederic Colombel, MD, Dana S. Hardin, MD Journal of the American Academy of Dermatology Volume 76, Issue 3, Pages 441-448.e2 (March 2017) DOI: 10.1016/j.jaad.2016.10.027 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Patient disposition. aPatient was determined to have a Hx of CD (not captured in the clinical database) by a gastroenterologist after the definitive event. bPatient was on 80-mg IXE Q4W during the induction period (after a 160-mg starting dose) then discontinued because of pregnancy and–69 days after discontinuing treatment–reported a flare of UC. CD, Crohn's disease; DC, discontinued; ETN, etanercept; Hx, history; IBD, inflammatory bowel disease; IXE, ixekizumab; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SAE, serious adverse event; TEAE, treatment-emergent adverse event; UC, ulcerative colitis. Journal of the American Academy of Dermatology 2017 76, 441-448.e2DOI: (10.1016/j.jaad.2016.10.027) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Crohn's disease. Treatment sequence and exposure days before the first event. Journal of the American Academy of Dermatology 2017 76, 441-448.e2DOI: (10.1016/j.jaad.2016.10.027) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 2 Ulcerative colitis. Treatment sequence and exposure days before the first event. Journal of the American Academy of Dermatology 2017 76, 441-448.e2DOI: (10.1016/j.jaad.2016.10.027) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions